Received Sep 10; Accepted Sep 23; Collection date Oct.
chenlv Product Page
© by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
PMCID: PMC PMID:Synephrine has been used to promote weight loss; however, its safety and efficacy have not been fully established. The goals of our study were to give an overview of the safety and efficacy of p-synephrine, to systematically evaluate its efficacy regarding weight loss and to assess its safety, focusing on its cardiovascular side effects in a meta-analysis. PubMed, the Cochrane Library, Web of Science and Embase were searched for relevant studies. Only placebo-controlled, human clinical trials with synephrine intervention were included in the meta-analysis. The meta-analysis was reported according to the PRISMA guidelines using the PICOS format and taking into account the CONSORT recommendations. Altogether, 18 articles were included in the meta-analysis. Both systolic and diastolic blood pressure (DBP) increased significantly after prolonged use (6.37 mmHg, 95% CI: 1.02'11.72, p = 0.02 and 4.33 mmHg, 95% CI: 0.48'8.18, p = 0.03, respectively). The weight loss in the synephrine group was non-significant after prolonged treatment, and it did not influence body composition parameters. Based on the analyzed clinical studies, synephrine tends to raise blood pressure and heart rate, and there is no evidence that synephrine can facilitate weight loss. Further studies are needed to confirm evidence of its safety and efficacy.
Keywords: p-synephrine, meta-analysis, obesity, food supplements, weight loss
The global increase in obesity is strongly connected to modifiable lifestyle factors, including sedentary lifestyle and diet [1]. Obesity is associated with serious health problems and related comorbidities [2,3], and even modest weight loss can result in improved systolic and diastolic blood pressure and blood cholesterol levels [4]. Increased physical activity, a low-calorie diet and the monitoring of body weight can facilitate weight loss in the long term [5].
Dietary supplements are easily available alternatives to medicines; however, data supporting their efficacy are usually scarce, and in some cases, their safety is also questionable [6]. Because of safety concerns, several Active Pharmaceutical Ingredients (APIs), that were considered as effective compounds to support weight loss are no longer available on the market. p-Synephrine, a protoalkaloid extracted from the immature fruit or peel of bitter orange (Citrus × aurantium L.), is widely used in weight loss and sports performance products [7], yet its efficacy and safety has not been fully established [8].
Synephrine exists in three different positional isomeric forms (ortho, meta and para) [9] (Figure 1). It is generally accepted that only para-synephrine (p-synephrine) can be found in bitter orange fruits [10,11,12]. Food supplements can contain meta (m)- and p-synephrine, which are both alpha-adrenergic agonists (α-agonists), while the m-isoform is the most potent on alpha-1-adrenoreceptors (α1-adrenergic receptors) [13]. Ortho-synephrine (o-synephrine) is not used as a pharmaceutical substance, and its natural occurrence has not been documented [13,14]. Methyl-synephrine HCl (4-HMP, syn. oxilofrine HCl) is a prohibited synthetic derivative of p-synephrine and has been reported as an adulterant in food supplements [15,16,17,18].
Since the use of ephedrine in food supplements has become prohibited in several European countries and in the USA, p-synephrine has gained considerable interest as the main substitute of ephedrine in weight loss products [12,19,20,21]. Synephrine is similar to ephedrine with regard to its structure and mechanism of action; however, it is less lipophilic, resulting in decreased transport through the blood'brain barrier [7,22,23,24]. The use of ephedrine is associated with the increased risk of myocardial infarction, hypertension, and stroke [12,25], but such pronounced effects on the cardiovascular system are not expected when using p-synephrine. Animal studies have shown that p-synephrine stimulates beta-adrenoreceptors, causing thermogenesis and lipolysis [7], whereas its cardiovascular adverse effects are partly due to its α-adrenergic receptor affinity [26]. Although it is generally acknowledged that p-synephrine has milder side effects than ephedrine, its safety and efficacy have not yet been thoroughly studied [8,19].
p-Synephrine (hereinafter referred to as synephrine) is used in pre-workout supplements to improve performance and to promote weight loss since it has thermogenic and sympathomimetic properties [27,28]. Synephrine was added to the Monitoring Program in Competitions of the World Anti-Doping Agency [29], but it is not yet considered as a prohibited substance (WADA) in [30]. However, it is prohibited for use by several professional sporting agencies (the National Collegiate Athletic Association (NCAA), Major League Baseball (MLB), and the National Football League (NFL)) [31].
Currently, there is little if any basis for making definitive statements about the safety of bitter orange extracts or synephrine used in food supplements [9]. Cardiac adverse events, including hypertension, tachyarrhythmia, variant angina, cardiac arrest, QT prolongation, ventricular fibrillation, myocardial infarction, and sudden death, have been the most common adverse effects associated with synephrine intake [27]; however, the prevalence is not known. The average synephrine content of the dried fruit extracts of Citrus aurantium has been reported to be between 3% and 6% [9,10,32,33,34]. The French food safety authority (ANSES) concluded in its assessment on synephrine [35] that the intake levels of synephrine from food supplements must remain below 20 mg/day, and it is not recommended to take synephrine in combination with caffeine. It is also recommended to avoid the use of products containing synephrine during physical exercise, and its use by sensitive individuals is discouraged (i.e., people taking certain medications, pregnant or breastfeeding women, children, and adolescents) [35,36]. Because of its known sympathomimetic properties and adrenergic effects on the cardiovascular system, the use of synephrine in food supplements is debated [36]. Even though there is no legislation which limits the content of synephrine and other alkaloids in dietary supplements, based on the Directive /46/EC, each country is supposed to set a maximum level of synephrine [37,38]. There have been reports in the RASFF (Rapid Alert System for Food and Feed) about synephrine, because in some countries, there is a limit regarding its daily dose, and in the reported cases, the products contained more than the maximum [39] (Table S1, Figure S1).
Electronic searches were conducted in the following databases: PubMed, Embase, Web of Science (WoS), and the Cochrane Library. Each database was searched until 17 August . The searching method included the key term synephrine. This meta-analysis of eligible peer reviewed studies was reported in accordance with the PRISMA statement and followed the CONSORT recommendations. Trials were selected if they were (1) human clinical studies, (2) compared known doses of orally used synephrine with a placebo or active control or both, and (3) completed. In order to complete this task, the following PICO (patients, intervention, comparison, outcome) format was applied: P: adults; I: known dosage of p-synephrine given per os; C: placebo or control; and O: changes in the body weight, composition, cardiovascular, and metabolic parameters (i.e., heart rate, blood pressure, body weight, body fat, fat mass, fat-free mass, fasting blood sugar level, and RER values). Our hypothesis was that synephrine facilitates weight loss and that its use correlated with cardiovascular adverse effects. This work was registered in PROSPERO (). There were no restrictions regarding the number of included patients or the minimal or maximal dosing of p-synephrine. The language of the included articles was restricted to English.
As clarified in the PICO, clinical trials involving adults were included in this meta-analysis. Of these clinical trials, outcomes related to the efficacy and safety of synephrine were extracted. The study endpoints included those values which were present in at least three articles and could be compared. Statistical evaluation could modify the finally analyzed trials/outcomes. The following information from individual studies was extracted: the first author's name and publication year; the study design and population; the number of participants; other medicines in the intervention group; synephrine regimen; and outcomes.
Two authors (D.K. and D.CS.) performed the literature search. Both authors reviewed the full-text articles and extracted appropriate data from the publications. The risk of bias was analyzed by two of the authors (D.CS. and B.T.), using the Cochrane Risk of Bias Tool, which includes the following domains: random sequence generation, allocation concealment, the blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective reporting and other scores of bias. For each domain, studies were judged to have a high (red), unclear (yellow), or low (green) risk of bias (Figure S2 and S3). Disagreements were resolved by consensus. Risk of bias figures were prepared by using the Review Manager (RevMan) version 5.4.1 software from Cochrane Training site based in London, UK.
An outcome was selected for the final analysis if it was reported in at least three articles; however, further attrition and unique time intervals could modify the analyzed study number/outcome. The assessment of weighted mean difference (MD) and effect sizes (ESs) between test and control group values (synephrine vs. control) was performed as a post'post analysis. A Chi2 or Tau2 test was used to evaluate the heterogeneity. Deviating study intervention arms were excluded from the final analysis in case there were other extra intervention(s) apart from synephrine (mainly caffeine). In the case of heterogenous subjects based on their caffeine usage, the regular non-caffeine users were selected contrasting to regular high caffeine users. The statistical analyses were conducted using the Review Manager 5.4.1 software. The results were considered statistically significant when the p value was less than 0.05.
The literature search resulted in the identification of articles (Figure 2). After duplicate removal, the screening of titles and abstracts resulted in the revision of 51 publications which were retrieved for full-text screening (excluded: n = ). The 51 full-text articles were assessed for eligibility. After the revision, 21 studies were found to be appropriate for qualitative analysis (excluded: n = 30). Articles were excluded if they were not peer reviewed scientific articles (i.e., abstracts or posters) (n = 2); were clinical trials but not with synephrine (n = 3); were not human clinical studies (n = 1); when there were time intervals that were too heterogeneous or did not indicate trial duration (n = 5). Further studies were excluded if they had missing statistical values (n = 1) or detailed outcomes (n = 7), or missing relevant outcomes (n = 4), they were not placebo-controlled trials (n = 3) or were not clinical studies (n = 4). Since one study [40] was open-label and in two studies, the authors did not give the exact dosage of synephrine [41,42], these studies were not eligible for further quantitative analyses. Therefore, a total of 18 studies involving 341 patients were included in the final quantitative analysis. Penzak et al. conducted a two-way, crossover, open-label trial and assessed the cardiovascular effect of approx. 13'14 mg synephrine, which did not significantly alter SBP, DBP, and HR in 12 healthy subjects [40]. Kliszczewicz et al. reported a randomized crossover trial investigating the effects of 100 mg of Citrus aurantium (CA) powder (with an unknown dosage of synephrine) compared to caffeine (100 mg) or a placebo. The consumption of Citrus aurantium caused a significant time-dependent increase in the HR of the test subjects [41]. In another randomized, double-blind trial, participants consumed 140 mL of a high-energy drink containing unknown dosages of methyl-synephrine [42]. Based on their results, significantly higher SBP was observed in the intervention group during the three-hour study period, but no significant changes were observed in HR or in DBP.
The 18 trials included were double-blinded, prospective, parallel or crossover, within-subjects or counterbalanced studies (Table S2). Seven trials were crossover [43,44,45,46,47,48,49]; five had parallel design [22,50,51,52,53]; four had within-subjects [54,55] or other [56,57] designs; and two were performed in a counterbalanced manner [58,59].
Fourteen trials assessed the acute effects of synephrine [43,44,45,46,47,48,49,53,54,55,56,57,58,59]. In four trials, the effect of a longer treatment duration (a range of 4'8 weeks) was assessed [22,50,51,52]. The daily dosage of synephrine ranged from 6 to 214 mg.
The inclusion criteria of the trials varied from trial to trial. Eight trials only included physically active subjects [22,45,49,50,52,54,56,59]. In eight trials, healthy, normotensive but not resistance-trained subjects were involved [43,44,46,48,51,53,55,57]. Four trials included overweight adults [22,47,52,58]. In several trials, other interventions were also studied, but these study arms were not included in our analysis [45,50,51,53,54,55,56]. Nine trials involved exercise training [22,45,49,50,52,56,57,58,59]. It is important to emphasize that while comparing weight loss and body compositions from the analyzed three articles [22,50,52], all of these trials included exercise intervention, and two involved dietary restrictions [22,52]. Nine trials did not include exercise intervention [43,44,46,47,48,51,53,54,55]. In seven trials, the main analyzed intervention contained substances other than synephrine (e.g., caffeine) [22,44,45,47,50,52,58]. One study [56] claimed that all participants were classified as low caffeine consumers (<50 mg/day), but in the rest of the trials, the authors did not specify whether the subjects were regular or non-regular caffeine users. Bush et al. () [54] and Ratamess et al. () [55] divided groups based on their average caffein consumption. However, the subgroup of regular high caffeine users (>300 mg) was excluded from our final meta-analysis to make the analyzed groups more homogenous. In seven trials, participants were requested to limit caffeine consumption [22,49,51,52,56,57,59].
In the 18 trials analyzed, the common inclusion criterion was the age of 18 years or older, and in every study, the inclusion procedure was in harmony with the Helsinki declaration. In eight cases, pregnant women were excluded [22,43,44,45,46,48,51,52], and also, smoking was an exclusion criterion; only non-smokers participated in nine trials [43,45,49,50,54,55,56,58,59]. The age of the analyzed participants was between 18 and 51 years. Participants were healthy, physically active/exercise trained or in fewer cases, healthy but sedentary and/or overweight. Additionally, more male patients were randomized (68.45%). Taking into consideration the crossover design and the within subject design, 341 subjects were analyzed (Table S3).
The meta-analyzed outcomes were SBP, DBP, HR, weight loss, body fat percentage, fat mass, fat-free mass, blood glucose, and RER values. In addition, several studies indicated other adverse events, but they were too heterogeneous to be statistically analyzed. These side effects included complaints of headaches [46], hyperventilation [58], racing HR, feelings of dizziness, and feelings of irritability or perspiration [55], palpitations, shortness of breath, nervousness, and blurred vision [50]. Other outcomes were increased VO2 uptake [45], increased energy expenditure [44], increased fat oxidation, reduced carbohydrate utilization [57,59], and changes in the ratings of perceived exertion [56,59]. However, the outcomes mentioned above were omitted from the final analysis, since these occurred in less than three articles or were based on other heterogeneous parameters (time intervals) or missing detailed outcomes.
Altogether, 11 trials with 222 subjects and six different time sets and heterogeneous dosages (a range of 10'214 mg) were used to assess the effects of synephrine on blood pressure. The SBP tended to increase in the synephrine group (Figure 3). It was found that 30'45 min after the administration of 20'50 mg of synephrine, the mean difference was 1.21 mmHg (95% CI: '2.57'5.00), which was not significant (p = 0.53) but showed a greater effect size for synephrine than for the placebo. After 1 h of the administration of the products containing 49'214 mg of synephrine, the post'post analysis showed a non-significant increase in the SBP (MD 1.56 mmHg, 95% CI: '1.11'4.24, p = 0.25). Based on five trials involving 61 subjects, the effect of synephrine (49'180 mg) remained non-significant (MD 3.89 mmHg, 95% CI: '0.99'8.77, p = 0.12) after 2 h. After 3 h of the administration, only a slight effect (MD 0.34 mmHg, 95% CI: '2.18'2.87, p = 0.79) on the SBP was observable, and it seems that the effect diminished after 6-8 h (MD 0.10 mmHg, 95% CI: '3.82'4.02, p = 0.96; dosage 27'108 mg) of consumption. Based on two trials involving 75 subjects, a daily dose of 10'49 mg of synephrine had a significant effect on the systolic blood pressure (MD 6.37 mmHg, 95% CI: 1.02'11.72, p = 0.02) after 8 weeks of administration.
The dosages and the included articles were the same in DBP; one difference was that we left one datum point out by 2 h [49], as the statistical SD value '0' could not have been estimated. The administration of synephrine (20'214 mg) did not significantly alter the DBP 30-45 min after administration (MD: '0.88 mmHg, 95% CI: '4.45'2.70, p = 0.63); 1 h after administration (MD: '0.89 mmHg, 95% CI: '2.92'1.13, p = 0.39); 2 h after administration (MD: 0.48 mmHg 95% CI: '2.22'3.17, p = 0.73) (four articles; 49 subjects; 49'108 mg); 3 h after administration (MD: 0.40 mmHg 95% CI: '1.83'2.62, p = 0.73); or 6-8 h after administration (MD: '0.43 mmHg 95% CI: '3.52'2.66, p = 0.78).
Based on two trials involving 75 participants, a significant effect was observed on DBP after the long-term (8 weeks) usage of 10'49 mg of synephrine (MD 4.33 mmHg, 95% CI: 0.48'8.18, p = 0.03) (Figure 4).
Overall, nine trials involving 129 persons with six different time durations and varying dosages of synephrine (range 20'214 mg) studied the effects of synephrine on heart rate. Significant differences between synephrine and the placebo were not reported; however, the heart rate slightly increased after 30 min'6 h from consumption in the synephrine group (Figure 5). It was found that 30'45 min after synephrine consumption (20'50 mg), the mean difference in heart rate was 3.15 beat/min (95% CI: '0.41'6.71, p = 0.08); and it was 1.11 beat/min (95% CI: '1.32'3.53, p = 0.37) 1 h after the consumption of varying doses (49'214 mg) of synephrine. After 2 h of the ingestion of 49'180 mg of synephrine, a non-significant rise in the heart rate was observed (MD 3.15 beat/min, 95% CI: '0.65'6.96, p = 0.10).
Based on four trials involving 43 subjects, 3 h after the consumption of 60'180 mg of synephrine, the synephrine-adjusted increase in heart rate was 3.48 beat/min (95% CI: '0.33'7.29, p = 0.07). The effects observed after 4 h (MD 3.25 beat/min, 95% CI: '2.86'9.35, p = 0.30) and after 6 h (MD 2.84 beat/min, 95% CI: '2.80'8.48, p = 0.32; range 49'108 mg) remained non-significant based on the articles involving these time points.
The effect of synephrine on weight loss was analyzed in three trials [22,50,52]. The trials lasted for several weeks (42'56 days or 6'8 weeks), and the daily dose of synephrine was 54 mg, 20 mg, and 10 (5 × 2) mg, respectively. Based on our meta-analysis, its effect on weight loss was non-significant (MD 0.60 kg, 95% CI: '5.62'6.83, p = 0.85) (Figure 6A). The consumption of synephrine only resulted in a slight decrease in body fat ('1.87%, 95% CI; '3.92'0.18, p = 0.07), and the effect was not statistically different from that of the placebo (Figure 6B).
The administration of synephrine (20 or 54 mg) did not result in significant changes in fat mass. The mean difference was '0.32 kg (95% CI: '3.76'3.11, p = 0.85) (Figure 6C). A low dosage of synephrine (10 and 20 mg) did not significantly change the fat-free mass based on the included trials (MD 0.47 kg, 95% CI: '4.19'5.13, p = 0.84) (Figure 6D).
Based on the included trials, blood glucose values were not changed significantly after the administration of 6'103 mg of synephrine. Blood glucose levels changed slightly but not significantly after 2'3 h of the consumption of synephrine (MD 4.62 mg/dL, 95% CI: '3.04'12.29, p = 0.24) with moderate heterogeneity (TAU2 = 30.32%) (Figure 7 and Figure S4). In the head-to-head studies, the effect of synephrine on blood and plasma glucose [45,54,58] was also not significant.
The acute effects of synephrine (6'60 mg) on the respiratory exchange ratio (RER) were studied in three trials [44,47,58]. The effect of synephrine was not significant after 1, nor after 2, nor after 3 h of administration. After 1 h of consumption, there was no difference (the mean difference was 0.00 (95% CI: '0.03'0.03, p = 0.91)), strengthened by a non-classical leave-one-out analysis. After 2 h, synephrine resulted in a '0.02 difference (95% CI: '0.12'0.09, p = 0.75), and after 3 h, synephrine resulted in a '0.02 difference (95% CI: '0.12'0.08, p = 0.73) (Figure S5).
Overall, the methodical quality of the trials included in our final quantitative analysis was reckoned to be acceptable, mostly with low or unclear risks of bias (Figures S2 and S3).
The random sequence generation was described in three studies [43,48,49], and the measures taken to ensure allocation concealment were given in eight trials [43,45,49,50,54,55,57,59]; therefore, the selection bias (i.e., random sequence generation or allocation concealment) in these studies was judged to be low. On the other hand, Sale et al. [58] failed to mention whether their study was randomized or not; therefore, it had a high risk of selection bias. In the remaining studies, the information to judge the selection bias was not available; therefore, these studies were reckoned to have unclear risks of selection bias.
Regarding to the performance bias, four studies [43,49,50,59] were judged to have low risks of bias, but in the case of 14 studies, it was not clear whether the treatment and the comparator were identical in size, shape, color, and odor, and who was blinded and until when was not clearly described; therefore, these studies were judged to have unclear risks of performance bias. Four studies had low risks of detection bias [43,46,56,57], but in the other 14 studies, it remained unclear whether the results were assessed in a blinded manner or not.
All the included studies showed low risks of attrition and reporting biases. Five studies had unclear risks of bias, since all of these studies were at least partly founded by pharmaceutical companies related to the studied products, but their influence on the study design, performance, and report are not clearly stated [48,53,54,55,58].
Overall, 18 trials involving 341 adults were analyzed to perform this meta-analysis. Different sets depending on each outcome were applied to assess the weight loss effects of synephrine and to establish its safety based on its effects on cardiovascular variables. Based on the literature, the commonly used doses of p-synephrine vary from 25 to 100'mg per day [16,60,61], while our analysis included 6'214 mg of synephrine. Based on our meta-analysis, synephrine did not significantly increase systolic blood pressure acutely, but it significantly increased in the long term (p = 0.02) (Figure 3). It had less significant acute effects on diastolic blood pressure and showed similarly significant effects when applied for longer durations (8 weeks) (p = 0.03) (Figure 4). After the acute administration of synephrine, the heart rate increased, but the change remained non-significant; the highest increase was measured 3 h after consumption (p = 0.07) (Figure 5). Our analysis led to the conclusion that the prolonged use of synephrine did not result in significant alterations in body weight and composition (Figure 6). Based on the analyzed data, the acute administration of synephrine did not change blood glucose and RER values (Figure 7 and Figure S5).
Synephrine's impacts on cardiovascular health can be predicted by looking at its effects on cardiovascular variables. Since the use of ephedrine is associated with the increased risk of cardiovascular morbidity and mortality, a similarly effective but safe alternative would be greatly appreciated [9,62]. The dosage used during weight loss analysis was 10'54 mg daily for 42'56 days, which nearly coincides with the dosage that resulted in cardiovascular adverse events (increased blood pressure) after 56'60 days after the administration of 10'49 mg of synephrine. Based on our results, the use of synephrine does not lack cardiovascular side effects; therefore, it may not be a safe alternative to ephedrine for those with predisposing comorbidities.
p-Synephrine-containing products are marketed for those aiming for higher energy utilization during low- to moderate-intensity exercise [8]. However, it is not yet proven that bitter orange or synephrine consumption can reduce body fat or promote weight loss [8]. Based on our meta-analysis, the prolonged use of synephrine does not result in significant weight loss (p = 0.85). A mean difference of 0.6 kg was observed in a total of 94 subjects (47 subjects/intervention with a daily dose of 10'54 mg of synephrine). Synephrine was ineffective in influencing body fat ('1.87%, n = 94, p = 0.07), fat mass ('0.32 kg, n = 69, p = 0.85), and fat-free mass ('0.47 kg, n = 78, p = 0.84).
Some results suggest that p-synephrine has the potential to maintain blood glucose levels by stimulating the uptake of excess blood glucose via insulin-dependent or -independent mechanisms in skeletal muscles [63]. Maintaining optimal blood glucose values would be beneficial, suggesting greater hepatic glucose release, which would be favorable during exercise [45,64]. Based on our results, consuming synephrine did not alter blood glucose levels significantly (p = 0.24), and blood glucose maintenance was not affected by the consumption of 6'103 mg of synephrine.
Higher RER values indicate that carbohydrates are being predominantly used as fuel, and lower RER values suggest lipid oxidation [65,66]. Physically active and trained subjects exhibit lower RER values than untrained sedentary subjects in response to comparable workloads [67,68,69]. Our analysis included three articles with 33 analyzed subjects overall. In these trials, the effects of synephrine were assessed after 1 h of consumption. After 2'3 h of consumption, data from only 20 subjects were available. Our results suggest that the consumption of 6-103 mg of synephrine does not modify RER values significantly. RER value changes in the studies were presumably related to caffeine, and all three of the analyzed trials administered a supplement which had additional caffeine in it [47].
The strengths of this systematic review with meta-analysis are that only data from published peer-reviewed articles were used, and all the included trials were double-blind trials. However, there are several limitations to the analysis. First, the studied products were different and contained varying doses (6'214 mg) of synephrine with different isometric forms. One study included both m- and p-synephrine [46], and one study examined the effects of methyl-synephrine HCl [44]. Only six studies included isolated p-synephrine [53,54,55,56,57,59]. In the remaining ten studies, the applied products (such as bitter orange extract) contained standardized synephrine [43,48,49] or were mixed with other substances [22,44,45,47,50,52,58]. The main limitation of the study was high attrition, and only a few studies assessed the same outcomes, resulting in relatively small plots. There were no mentions of the the subjects' ethnicities, which weakens the results, as it is not clear if the groups were diverse enough in this regard. On the other hand, subjects showed a high variety of traits regarding physical activity and age, and more males were analyzed. Some trials included an exercise intervention, which made the data more heterogonous. Previously, Stohs et al. performed a detailed systematic review of synephrine, but there was no meta-analysis on this topic with statistical evaluations; only a literature review was performed [70]. The only available meta-analysis examined oral phenylephrine on nasal airway resistance in patients with nasal congestion, which did not examine p-synephrine and did not analyze its weight loss effects [71].
After the ban of Ephedra sinica by the FDA in , there was a clear need for an alternative weight loss supplement with favorable safety profile [12,25]. Synephrine was widely used to promote weight loss, and it is often considered as a safe and effective option, but its safety and efficacy is yet to be studied. When applying synephrine, it should be taken into account that it also has sympathomimetic effects, so it may also increase systolic blood pressure, diastolic blood pressure, and heart rate. Consequently, it may also increase the risk for stroke and myocardial infarction and therefore harm the consumers' health. Hence, the hemodynamic effects of bitter orange and p-synephrine must be established, but unfortunately, studies related to synephrine-induced cardiotoxicity are scarce [27,43].
p-Synephrine showed a tendency to increase systolic blood pressure and heart rate acutely, and it significantly increased both systolic and diastolic blood pressure when applied for longer durations. Therefore, our meta-analysis revealed safety concerns related to the use of synephrine. The beneficial effects of synephrine were rather inconclusive. In our meta-analysis, it did not promote weight loss, and neither did it cause beneficial effects on body composition. The overall effects on glucose and RER values were not proved to be favorable. The currently available evidence indicates that synephrine influences blood pressure and heart rate but has no significant effects on weight loss and body composition; therefore, its use is not recommended to promote health. Considering the limitations, it is concluded that further and larger trials are needed to assess the efficacy and safety of synephrine with a lower risk of bias.
The following supporting information can be downloaded at: https://www.mdpi.com/article/10./nu/s1, Table S1: Unauthorized synephrine (above maximal limit) products in the European Union in the RASFF system from to ; Table S2: Characteristics of the trials; Table S3: Demography of patients; Figure S1. Unauthorized synephrine (above maximal limit) products in the RASFF system from to (accessed on 31 December ).; Figure S2: Risk of bias graph on synephrine meta-analysis; Figure S3: Risk of bias summary on synephrine meta-analysis; Figure S4: Forest plot diagram of synephrine on (h/2) blood glucose for short duration in intervention and control groups with one change in the time duration; Figure S5: Forest plot diagram of synephrine on (i) RER values after 1'3 h (1 h two times with one change in time interval) in intervention and control groups.
Conceptualization, D.K. and D.C.; methodology, D.C.; software, M.A.B. and B.T.; formal analysis, D.K.; investigation, D.K. and D.C.; data curation, B.T., D.C. and M.A.B.; writing'original draft preparation, D.K.; writing'review and editing, D.C., O.R. and B.T.; visualization, B.T., M.A.B. and D.K.; supervision, O.R. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
Project No. TKP-EGA-32 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP-EGA funding scheme.
Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This section collects any data citations, data availability statements, or supplementary materials included in this article.
The data presented in this study are available in this article and in the Supplementary Material.
Articles from Nutrients are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)
Scheiber MD, Liu JH, Subbiah MT, et al. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause ;8:384-92. View abstract.
Secreto G, Chiechi LM, Amadori A, et al. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. Maturitas ;47:11-20. View abstract.
Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr ;131:S-75S. View abstract.
Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr ;129:758S-67S. View abstract.
Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet ;350:23-7. View abstract.
Setchell KD. Absorption and metabolism of soy isoflavones-from food to dietary supplements and adults to infants. J Nutr ;130:654S-5S. View abstract.
Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol - A clue to the effectiveness of soy and its isoflavones. J Nutr ;132:-84. View abstract.
Setchell KDR, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr ;78:593S-609S. View abstract.
Shao ZM, Shen ZZ, Fontana JA, Barsky SH. Genistein's "ER-dependent and independent" actions are mediated through ER pathways in ER-positive breast carcinoma cell lines. Anticancer Res ;20:-16. View abstract.
Shelnutt SR, Cimino CO, Wiggins PA, et al. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr ;76:588-94.. View abstract.
Shenoy S, Bedi R, Sandhu JS. Effect of soy isolate protein and resistance exercises on muscle performance and bone health of osteopenic/osteoporotic post-menopausal women. J Women Aging. ;25(2):183-98. View abstract.
Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev ;10:483-88. View abstract.
Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry ;60:191-3. View abstract.
Simão AN, Lozovoy MA, Bahls LD, et al. Blood pressure decrease with ingestion of a soya product (kinako) or fish oil in women with the metabolic syndrome: role of adiponectin and nitric oxide. Br J Nutr. ;108(8):-42. View abstract.
Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol ;85:-301. View abstract.
Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol ;85:-301. View abstract.
Sirtori CR, Pazzucconi F, Colombo L, et al. Double-blind study of the addition of high-protein soya milk v. cows' milk to the diet of patients with severe hypercholesterolemia and resistance to or intolerance of statins. Br J Nutr ;82:91-6. View abstract.
Slavin J. Nutritional benefits of soy protein and soy fiber. J Am Diet Assoc. ;91(7):816-9. View abstract.
Smith LJ, Holbrook JT, Wise R, et al. Dietary intake of soy genistein is associated with lung function in patients with asthma. J Asthma ;41:833-43. View abstract.
Smith LJ, Kalhan R, Wise RA, et al.; American Lung Association Asthma Clinical Research Centers. Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. JAMA. ;313(20):-43. View abstract.
Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol ;97:109-15. View abstract.
Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci ;95:238-42. . View abstract.
Soroka N, Silverberg DS, Greemland M, et al. Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients. Nephron ;79:173-80. View abstract.
Spence LA, Lipscomb ER, Cadogan J, et al. The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: a randomized crossover study. Am J Clin Nutr ;81:916-22. View abstract.
St Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause ;8:17-26. View abstract.
Stearns V, Hayes DF. Cooling off hot flashes. J Clin Oncol ;20:-8. View abstract.
Stephenson TJ, Anderson JW, Fanti P. Soy protein use in early diabetic nephropathy. Altern Ther Health Med ;7:S31-2.
Strom BL, Schinnar R, Ziegler EE, et al. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. JAMA ;286:807-14. View abstract.
Are you interested in learning more about Citrus Aurantium Extract Powder? Contact us today to secure an expert consultation!
Sun CL, Yuan JM, Arakawa K, et al. Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev ;11:-7. View abstract.
Tahavorgar A, Vafa M, Shidfar F, et al. Whey protein preloads are more beneficial than soy protein preloads in regulating appetite, calorie intake, anthropometry, and body composition of overweight and obese men. Nutr Res ; 34(10):856-61. View abstract.
Tai TY, Tsai KS, Tu ST, et al. The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study. Osteoporos Int. ;23(5):-80. View abstract.
Takatsuka N, Nagata C, Kurisu Y, et al. Hypocholesterolemic effect of soymilk supplementation with usual diet in premenopausal normolipidemic Japanese women. Prev Med ;31:308-14. View abstract.
Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. ;19(7):776-90. View abstract.
Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr ;85:-56. View abstract.
Tang J, Wan Y, Zhao M, Zhong H, Zheng JS, Feng F. Legume and soy intake and risk of type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Am J Clin Nutr. ;111(3):677-688. View abstract.
Tanos V, Brzezinski A, Drize O, et al. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol ;102:188-94. View abstract.
Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J Clin Endocrinol Metab ;90:-41. View abstract.
Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab ;86:-60. View abstract.
Teixeira SR, Potter SM, Weigel R, et al. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr ;71:-84. View abstract.
Teixeira SR, Tappenden KA, Carson L, et al. Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J Nutr ;134:-80. View abstract.
Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab ;83:-35. View abstract.
Thorp AA, Howe PR, Mori TA, et al. Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers. Am J Clin Nutr ;88:298-304. View abstract.
Tikkanen MJ, Wahala K, Ojala S, et al. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci USA ;95:-10.. View abstract.
Tonstad S, Smerud K, Hoie L. A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. Am J Clin Nutr ;76:78-84. View abstract.
Tranche S, Brotons C, Pascual de la Pisa B, Macías R, Hevia E, Marzo-Castillejo M. Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial. Gynecol Endocrinol. ;32(6):477-82. View abstract.
Travis RC, Allen NE, Appleby PN, et al. A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer ;122:705-10. View abstract.
Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst ;98:459-71. View abstract.
Tsai AC, Vinik AI, Lasichak A, Lo GS. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients. Am J Clin Nutr ;45:596-601. View abstract.
Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril ;82:145-8. View abstract.
Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study. Menopause ;7:236-42. View abstract.
Upson K, Sathyanarayana S, Scholes D, Holt VL. Early-life factors and endometriosis risk. Fertil Steril. ;104(4):964-971.e5. View abstract.
van der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, et al. Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women. Circulation ;111:465-71. View abstract.
Van Horn L, Liu K, Gerber J, et al. Oats and soy in lipid-lowering diets for women with hypercholesterolemia: is there synergy? J Am Diet Assoc ;101:-25. View abstract.
Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol ;20:-55. View abstract.
Vanderhoof JA, Murray ND, Paule CL, et al. Use of soy fiber in acute diarrhea in infants and toddlers. Clin Pediatr (Phila) ;36:135-9. View abstract.
Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al. CuraTrial Research Group. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause ;12:412-20. View abstract.
Vincent A, Fitzpatrick LA. Soy isoflavones: are they useful in menopause? Mayo Clin Proc ;75:-84. View abstract.
Vincent A, Ruan M, Fitzpatrick LA. Genistein, a phytoestrogen, inhibits proliferation of vascular smooth muscle cells: a possible cardioprotective mechanism. Fertil Steril ;74:S25.
Vitolins MZ, Griffin L, Tomlinson WV, et al. Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol. ;31(32):-8. View abstract.
Walker SE, Shulman KI, Tailor SA, Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol ;16:383-8. View abstract.
Wang G, Xiao CQ, Li Z, et al. Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers. Ann Pharmacother ;43:-9. View abstract.
Wang X , Liang QF , Zeng X , et al. Effects of soy isoflavone supplementation on patients with diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. Food Funct ;12(17):-. View abstract.
Wang X, Lv J, Yu C, et al. Dietary soy consumption and cardiovascular mortality among Chinese people with type 2 diabetes. Nutrients ;13(8):. View abstract.
Wang X, Yu C, Lv J, et al. Consumption of soy products and cardiovascular mortality in people with and without cardiovascular disease: a prospective cohort study of 0.5 million individuals. Eur J Nutr ;60(8):-. View abstract.
Wang Y, Guo J, Yu F, et al. The association between soy-based food and soy isoflavone intake and the risk of gastric cancer: a systematic review and meta-analysis. J Sci Food Agric ;101(13):-. View abstract.
Wang Y, Luo B, Xiang J. The association between soy intake and risk of gestational diabetes mellitus: a prospective cohort study. BMC Pregnancy Childbirth ;21(1):695. View abstract.
Wang ZV, Scherer PE. Adiponectin, Cardiovascular Function, and Hypertension. Hypertension. ;51:8-14.
Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr ;73:225-31. View abstract.
Wangen TE, Duncan AM, Merz-Demlow BE, et al. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocrinol Metab ;85:-8. View abstract.
Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause ;6:7-13. View abstract.
Weaver CM, Elmore D, Spence LA, et al. Effects of soy isoflavones on calcium metabolism and bone resorption in postmenopausal women. Altern Ther Health Med ;7:S35.
Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr ;57:940-6. View abstract.
Wei P, Liu M, Chen Y, Chen DC. Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pac J Trop Med. ;5(3):243-8. View abstract.
Weng KG, Yuan YL. Soy food intake and risk of gastric cancer: A dose-response meta-analysis of prospective studies. Medicine (Baltimore). ;96(33):e. View abstract.
White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr ;19:242-55. View abstract.
White MC, Etzel RA, Olson DR, Goldstein IF. Re-examination of epidemic asthma in New Orleans, Louisianna, in relation to the presence of soy at the harbor. Am J Epidemiol ;145:432-8. View abstract.
Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause ;13:831-9. View abstract.
Wiseman H, O'Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr ;72:395-400. View abstract.
Wong WC, Wong EL, Li H, et al. Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Complement Med. ;18(1):54-60. View abstract.
Wong WW, Smith EO, Stuff JE, et al. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Am J Clin Nutr ;68:S-9. View abstract.
Wu AH, Spicer D, Garcia A, et al. Double-blind randomized 12-month soy intervention had no effects on breast MRI fibroglandular tissue density or mammographic density. Cancer Prev Res (Phila). ;8(10):942-51. View abstract.
Wu AH, Stanczyk FZ, Hendrich, S et al. Effects of soy foods on ovarian function in premenopausal women. Br J Cancer ;82:-86. View abstract.
Wu AH, Stanczyk FZ, Martinez C, et al. A controlled 2-mo dietary fat reduction and soy food supplementation study in postmenopausal women. Am J Clin Nutr ;81:-41. View abstract.
Wu AH, Yang D, Pike MC. A meta-analysis of soyfoods and risk of stomach cancer: the problem of potential confounders. Cancer Epidemiol Biomarkers Prev ;9:-8. View abstract.
Wu SH, Liu Z. Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies. Nutr Cancer. ;65(5):625-32. View abstract.
Xiong J, Xu Y, Liu X, et al. Prospective association of dietary soy and fibre intake with puberty timing: a cohort study among Chinese children. BMC Med ;20(1):145. View abstract.
Xiong P, Zhu YF. Soy diet for nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore) ;100(22):e. View abstract.
Xu WH, Zheng W, Xiang YB, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. BMJ ;328:. View abstract.
Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev ;9:781-6. View abstract.
Xu X, Wang HJ, Murphy PA, Hendrich S. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr ;130:798-801. View abstract.
Xue T, Wen J, Wan Q, et al. Association of soy food with cardiovascular outcomes and all-cause mortality in a Chinese population: a nationwide prospective cohort study. Eur J Nutr ;61(3):-. View abstract.
Yagami A, Suzuki K, Nakamura M, et al. Case of anaphylactic reaction to soy following percutaneous sensitization by soy-based ingredients in cosmetic products. J Dermatol. ;42(9):917-8. View abstract.
Yamagiwa Y, Sawada N, Shimazu T, et al. Soy Food Intake and Pancreatic Cancer Risk: The Japan Public Health Center-based Prospective Study. Cancer Epidemiol Biomarkers Prev. ;29(6):-. View abstract.
Yamamoto S, Sobue T, Kobayashi M, et al. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst ;95:906-13. View abstract.
Zand RS, Jenkins DJ, Diamandis EP. Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat ;62:35-49. View abstract.
Zarei A, Stasi C, Mahmoodi M, Masoumi SJ, Zare M, Jalali M. Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Iran J Basic Med Sci. ;23(10):-. View abstract.
Zhang FF, Haslam DE, Terry MB, et al. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer. Mar 6. doi: 10./cncr.. View abstract.
The Federal Institute for Risk Assessment (Bundesinstitut fur Risikobewertung - Germany). Health assessment of sports and weight loss products containing synephrine and caffeine. . BfR Opinion No. 004/.
Uckoo RM, Jayaprakasha GK, Nelson SD, Patil BS. Rapid simultaneous determination of amines and organic acids in citrus using high-performance liquid chromatography. Talanta ;83(3):948-54. View abstract.
Vatsavai LK, Kilari EK. Interaction of p-synephrine on the pharmacodynamic and pharmacokinetics of gliclazide in animal models. J Ayurveda Integr Med ; S-(16)-9. doi: 10./j.jaim..04.010.View abstract.
Vierck JL, Icenoggle DL, Bucci L, Dodson MV. The effects of ergogenic compounds on myogenic satellite cells. Med Sci Sports Exerc ;35:769-76. View abstract.
Visentin V, Morin N, Fontana E, et al. Dual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J Pharmacol Exp Ther ;299:96-104. View abstract.
Vitetta L, Thomsen M, Sali A. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust ;178:411-2.. View abstract.
Zhang L, Xu X, Jiang T, et al. Citrus aurantium Naringenin Prevents Osteosarcoma Progression and Recurrence in the Patients Who Underwent Osteosarcoma Surgery by Improving Antioxidant Capability. Oxid Med Cell Longev. ;:. View abstract.
Zhao XW, Li JX, Zhu ZR, et al. Anti-shock effects of synthetic effective compositions of fructus aurantii immaturus. Experimental study and clinical observation. Chin Med J (Engl) ;102:91-3. View abstract.
For more Sodium Deoxycholateinformation, please contact us. We will provide professional answers.